Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04007536 · ClinicalTrials.gov registry record
A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
A clinical trial, sponsored by Denali Therapeutics.
- Completed
- Registry status
- 18
- Enrollment target
NCT04007536 is a clinical trial that has completed, run by Denali Therapeutics. The registered enrollment target is 18 participants.
The verdict
NCT04007536 has completed, sponsored by Denali Therapeutics.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
Study Summary
This is a six-part prospective, multicenter, multiregional observational study of patients with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, to assess biomarkers potentially related to disease severity and/or treatment response and prospectively assess the progression of disease in participants with MPS II who are aged ≤30 years at the time of enrollment.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-10-23 |
| Est. Completion | 2024-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04007536
The ClinicalTrials.gov registry entry for NCT04007536 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Denali Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT04007536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04007536 about?
NCT04007536 is a clinical study titled "A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome". This is a six-part prospective, multicenter, multiregional observational study of patients with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, to assess biomarkers potentially related to disease severity and/or treatment response and prospectively assess the progression of di...
What is the current status of trial NCT04007536?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2019-10-23. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT04007536?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04007536?
This trial is sponsored by Denali Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.